ClinicalTrials.gg
CompletedNCT00942305Updated Jul 16, 2021Results posted

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

A Phase 2 interventional study of Brincidofovir and Placebo in Cytomegalovirus Infection, sponsored by Chimerix. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 178 studies in Cytomegalovirus Infections with a site in United States — 15 open to participants now, 21 under way, 2 of them phase 3. Cytomegalovirus Infections · United States.

Enrollment
25th of 139
239 · median 61
Started
2009
with 2 others
Phase 2
36 of 178
3 open now
Registered
92nd of 178
by date
Lead sponsor
3 of 178
Chimerix

Among the 178 studies in Cytomegalovirus Infections with a site in United States, this one is the 25th largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2009, is one of 36 in phase 2, and was the 92nd registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

15 of the 178 studies in Cytomegalovirus Infections with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies in Cytomegalovirus Infections with a site in United States, or all of them as a file.
02

Study summary

This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks. Dosing was initiated immediately following engraftment (between Days 14-30 post-transplant) to prevent/control cytomegalovirus (CMV) infection or prevent disease in R+ hematopoietic stem cell transplant (HCT) recipients.

Read the detailed description

This was to be a 2-part study. Part 1 was a randomized, double-blind, placebo-controlled, dose-escalation study of multiple doses of oral brincidofovir (BCV) in R+ hematopoietic stem cell transplant (HCT) recipients. In Part 2, one of the dose levels administered in Part 1 was to be tested against placebo to evaluate the statistical significance of BCV as a therapy for preventing progression of cytomegalovirus (CMV) infection or preventing CMV disease. The first 3 dose-escalating cohorts in Part 1 were to include 32 subjects within each cohort (24 randomized to receive oral BCV and 8 randomized to receive placebo in a 3:1 ratio) for a total of 96 planned subjects. Following completion of the first 3 cohorts and subsequent safety review of the data, up to an additional 3 cohorts of 32 subjects each could have been enrolled. Two additional cohorts (labeled Cohort 4 and Cohort 4A) beyond the initial 3 cohorts were actually enrolled in Part 1 of the study. Following the safety and antiviral activity analyses of the 5 cohorts in Part 1 and the number of subjects enrolled in each of those cohorts, Part 2 of the study was not conducted.

03

Conditions studied

  • Cytomegalovirus Infection

Keywords

  • Allogeneic stem cell transplant
  • CMV seropositive (R+)
  • transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion into the study, all prospective subjects were required to fulfill all of the following criteria (as applicable):

  1. Were aged ≥18 years. Males must have been able and willing to use adequate methods throughout the treatment and follow-up phases of the study.
  2. Were cytomegalovirus (CMV) seropositive before hematopoietic stem cell transplantation (HCT) (i.e., R+ subjects).
  3. Were less than 30 days post qualifying transplant.
  4. Had evidence of engraftment before randomization and receiving their first dose of study drug.
  5. Were able to ingest and absorb oral medication (in the judgment of the investigator and based on lack of significant gastrointestinal [GI] events).
  6. Were willing and able to understand and provide written .
  7. To the best of his or her knowledge, were willing and able to participate in all required study activities for the duration of the study.

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the following exclusion criteria were to be excluded from participation in the study:

  1. Females who were pregnant or currently nursing.
  2. Had a >35 kg/m2. [Note: This criterion was removed per Protocol Amendment 2 dated 27 August 2010.]
  3. Had to cidofovir (CDV) or brincidofovir.
  4. Recipients for whom the current, predose clinical course of CMV infection suggested that the investigator would not be able to withhold treatment for CMV for a minimum of 5, but preferably 7 days following the subject's first dose of study drug.
  5. Received any of the following:

    • Ganciclovir, valganciclovir, foscarnet or CDV within 14 days prior to enrollment;
    • Any anti-CMV therapy following transplantation (including Cytogam®1);
    • Any CMV vaccine;
    • Any drug with antiviral activity against double-stranded DNA (dsDNA) viruses within 14 days prior to enrollment. [Note: An investigational drug was defined as a drug that was not approved for any indication by the Food and Drug Administration.]; or
    • Any other investigational drug (i.e., those without any "anti-dsDNA virus" activity; e.g., anti-influenza compounds) within 14 days prior to enrollment without the prior written consent of the medical monitor. The use of investigational drugs in certain circumstances was added per Protocol Amendment 1 dated 15 January 2010.
  6. Received high dose acyclovir (>2000 mg total oral daily dose or >5 mg/kg intravenously 3 times daily) or valacyclovir (Valtrex; >3000 mg total daily dose) at the time of dosing.
  7. Were diagnosed with active CMV disease within 6 months prior to enrollment; patients with CMV DNAemia requiring intervention with antiviral therapy at the time of enrollment.
  8. Were positive; patients with active virus (HCV) or virus (HBV) infection as evidenced by plasma levels of HCV RNA or HBV DNA, respectively.
  9. Received another HCT within the past 2 years, other than the qualifying HCT.
  10. Had renal insufficiency as evidenced by (GFR) \<30 mL/min.
  11. Had a current diagnosis of hypotony, uveitis, or retinitis or any intraocular pathology that would predispose the subject to any one of these conditions.
  12. Had hepatic dysfunction as evidenced by or aspartate aminotransferase >5 x the (ULN) or direct >2.5 x the ULN.
  13. Had any of the following active disorders: myasthenia gravis, Addison's disease, Wegener's granulomatosis, primary biliary cirrhosis, bullous pemphigoid, autoimmune hemolytic anemia, autoimmune hepatitis, multiple sclerosis, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, lupus erythematosus, dermatomyositis, polymyositis, or vasculitis.
  14. Had active solid tumor with the exception of basal cell carcinoma or the condition under treatment (e.g., lymphomas).
  15. Had 1 or more episode of hyperglycemic coma or diabetic ketoacidosis within the 6 months prior to enrollment.
  16. Had cardiovascular disease which, in the opinion of the investigator, would interfere with the conduct of the study.
  17. Had Grade 3 or 4 of the GI tract; subjects with any GI disease that would, in the judgment of the investigator, preclude the subject from taking or absorbing oral medication (e.g. clinically active Crohn's disease, ischemic colitis, moderate or severe ulcerative colitis, or any condition expected to require abdominal surgery during the course of study participation).
  18. Any other condition including abnormal laboratory values that would have, in the judgment of the investigator, put the subject at increased risk for participating in the trial, or interferes with the conduct of the trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
239 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    * Cohort 1 = 40 mg of matching placebo administered once weekly (QW) * Cohort 2 = 100 mg of matching placebo administered QW * Cohort 3 = 200 mg of matching placebo administered QW * Cohort 4 = 200 mg of matching placebo administered twice weekly (BIW) * Cohort 4A = 100 mg of matching placebo administered BIW

    Drug: Placebo

  • Experimental
    Brincidofovir

    * Cohort 1 = 40 mg brincidofovir (BCV) administered once weekly (QW) * Cohort 2 = 100 mg BCV administered QW * Cohort 3 = 200 mg BCV administered QW * Cohort 4 = 200 mg BCV administered twice weekly (BIW) * Cohort 4A = 100 mg BCV administered BIW

    Drug: Brincidofovir

Interventions

  • Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.

    Also known as: BCV, CMX001

  • DrugPlacebo

    Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant. Matching placebo administered for each cohort.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant CMV Infection

    The primary efficacy endpoint was a binomial outcome of failure to prevent cytomegalovirus (CMV) infection defined as CMV DNAemia \>200 copies/mL obtained at the time of the last treatment with study drug or diagnosis of CMV disease at some point during the treatment phase.

    Time frame: Randomization to Week 8 post-treatment (~19 weeks)

07

Results

Posted Jul 16, 2021

Participant flow

Note: While a total of 239 subjects were enrolled, 1 center was excluded from analysis due to concerns about investigator/site compliance with the study protocol. This center had enrolled 9 subjects: 5 subjects who received brincidofovir (BCV) in Cohort 1, 2 subjects who received placebo in Cohort 1, and 2 subjects who received BCV in Cohort 2.

Participant flow — Overall Study
MilestoneCohort 1 BCVCohort 1 PlaceboCohort 2 BCVCohort 2 PlaceboCohort 3 BCVCohort 3 PlaceboCohort 4 BCVCohort 4 PlaceboCohort 4aCohort 4a Placebo
Started30102910391430105017
Completed7514414965257
Not completed2351562552452510

Outcome measures

PrimaryNumber of Participants With Clinically Significant CMV Infection

The primary efficacy endpoint was a binomial outcome of failure to prevent cytomegalovirus (CMV) infection defined as CMV DNAemia \>200 copies/mL obtained at the time of the last treatment with study drug or diagnosis of CMV disease at some point during the treatment phase.

Time frame:
Randomization to Week 8 post-treatment (~19 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant CMV Infection
ParticipantsCohort 1 BCVCohort 1 PlaceboCohort 2 BCVCohort 2 PlaceboCohort 3 BCVCohort 3 PlaceboCohort 4 BCVCohort 4 PlaceboCohort 4a BCVCohort 4a Placebo
Number of Participants With Clinically Significant CMV Infection134641247357

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 BCV—12/25 (48%)25/25 (100%)
Cohort 1 Placebo—4/8 (50%)8/8 (100%)
Cohort 2 BCV—10/27 (37%)27/27 (100%)
Cohort 2 Placebo—6/10 (60%)9/10 (90%)
Cohort 3 BCV—19/39 (48.7%)39/39 (100%)
Cohort 3 Placebo—6/14 (42.9%)14/14 (100%)
Cohort 4 BCV—21/30 (70%)30/30 (100%)
Cohort 4 Placebo—3/10 (30%)10/10 (100%)
Cohort 4a BCV—30/50 (60%)50/50 (100%)
Cohort 4a Placebo—8/17 (47.1%)17/17 (100%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventCohort 1 BCVCohort 1 PlaceboCohort 2 BCVCohort 2 PlaceboCohort 3 BCVCohort 3 PlaceboCohort 4 BCVCohort 4 PlaceboCohort 4a BCVCohort 4a Placebo
Acute graft versus host diseaseImmune system disorders0/250/80/270/103/390/1412/300/1015/502/17
DiarrhoeaGastrointestinal disorders0/250/80/270/101/390/1410/300/105/501/17
PyrexiaGeneral disorders0/251/80/272/103/390/141/302/102/502/17
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/250/80/270/100/392/140/300/102/500/17
Abdominal painGastrointestinal disorders0/251/80/270/100/390/140/300/101/501/17
VomitingGastrointestinal disorders0/251/80/270/100/390/142/300/101/500/17
Graft versus host diseaseImmune system disorders1/251/80/270/100/390/140/300/100/500/17
BacteraemiaInfections and infestations0/251/81/270/100/390/140/300/100/500/17
Viral haemorrhagic cystitisInfections and infestations1/251/80/270/100/390/140/300/100/500/17
ThrombocytopeniaBlood and lymphatic system disorders1/250/80/271/100/390/141/300/100/501/17
Most frequent other events
Showing 10 of 241
Most frequent other events
EventCohort 1 BCVCohort 1 PlaceboCohort 2 BCVCohort 2 PlaceboCohort 3 BCVCohort 3 PlaceboCohort 4 BCVCohort 4 PlaceboCohort 4a BCVCohort 4a Placebo
Acute graft versus host diseaseImmune system disorders0/250/80/270/104/390/1424/302/1032/506/17
DiarrhoeaGastrointestinal disorders3/252/88/274/1013/394/1421/302/1026/504/17
VomitingGastrointestinal disorders2/251/86/272/106/394/148/301/1022/503/17
Cytomegalovirus viraemiaInfections and infestations10/252/84/272/107/393/145/300/106/504/17
Abdominal painGastrointestinal disorders4/251/82/270/105/391/1411/300/1013/502/17
NauseaGastrointestinal disorders6/251/85/271/1011/394/1411/303/1017/503/17
Alanine aminotransferase increasedInvestigations2/250/81/270/102/390/1410/300/109/501/17
PyrexiaGeneral disorders1/251/81/273/107/391/142/302/1010/504/17
Acute graft versus host disease in skinImmune system disorders4/252/83/273/107/390/140/300/100/500/17
Cytomegalovirus infectionInfections and infestations0/250/82/272/104/392/142/303/102/501/17

Baseline characteristics

Note: While a total of 239 subjects were enrolled, 1 center was excluded from analysis due to concerns about investigator/site compliance with the study protocol. This center had enrolled 9 subjects: 5 subjects who received brincidofovir (BCV) in Cohort 1, 2 subjects who received placebo in Cohort 1, and 2 subjects who received BCV in Cohort 2.

Age, Continuous
Age, Continuous(years)Cohort 1 BCVCohort 1 PlaceboCohort 2 BCVCohort 2 PlaceboCohort 3 BCVCohort 3 PlaceboCohort 4 BCVCohort 4 PlaceboCohort 4a BCVCohort 4a PlaceboTotal
Mean56.3 ± 10.0256.8 ± 10.1251.7 ± 10.1353.5 ± 11.0849.5 ± 12.7547.9 ± 14.0550.4 ± 11.4752.2 ± 14.7648.8 ± 12.7446.1 ± 12.1450.7 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 BCVCohort 1 PlaceboCohort 2 BCVCohort 2 PlaceboCohort 3 BCVCohort 3 PlaceboCohort 4 BCVCohort 4 PlaceboCohort 4a BCVCohort 4a PlaceboTotal
Female10110517912324798
Male1571752251872610132
08

Study locations

26 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Moores UCSD Cancer Center
    La Jolla, California 92093, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Winship Cancer Institute at Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Brigham and Womens Hospital, Division of Infectious Disease
    Boston, Massachusetts 02115, United States
  • University of Michigan Medical School
    Ann Arbor, Michigan 48109, United States
  • Harper University Hospital
    Detroit, Michigan 48201, United States
  • University of Minnesota Medical Center
    Minneapolis, Minnesota 55455, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68198-5130, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Montefiore Medical Center Oncology
    Bronx, New York 10467, United States
  • Mt. Sinai School of Medicine
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • UNC Health Care Center
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27517, United States
  • The Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390-8565, United States
  • University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Utah Cancer Specialists - Intermountain Healthcare
    Salt Lake City, Utah 84088, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Lanier ER, Foster S, Brundage T, Chou S, Prichard MN, Kleiboeker S, Wilson C, Colville D, Mommeja-Marin H. Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. J Infect Dis. 2016 Jul 1;214(1):32-5. doi: 10.1093/infdis/jiw073. Epub 2016 Mar 3. PubMed 26941282 ↗
  • Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Mommeja-Marin H, Boeckh M; CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688. PubMed 24066743 ↗
  • Tippin TK, Morrison ME, Brundage TM, Mommeja-Marin H. Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies. Ther Drug Monit. 2016 Dec;38(6):777-786. doi: 10.1097/FTD.0000000000000353. PubMed 27851688 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Jan 2012, 27 months.

Results were first posted in Jul 2021, 9 years 6 months after primary completion.

Of 29 phase 2 interventional studies under Cytomegalovirus Infections, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 62. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2009
First posted
Jul 20, 2009
StartActual
Oct 2009
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Jul 16, 2021
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00942305
Lead sponsor
Chimerix
Responsible party
Sponsor
First posted
Jul 20, 2009
Start date
Oct 2009
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Jul 16, 2021
Last update
Jul 16, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion